Portfolio reprioritisations and last-minute protocol amendments are the norm at your scale, not the exception. We adjust the plan the moment scope shifts, because our therapeutic leads hold the authority to make the call on the spot, not three approvals later.

Running dozens of studies across multiple CROs can turn any single programme into a line on someone else’s dashboard. We assign senior therapeutic leads who know your indication and stay accountable to your programme specifically, not spread thin across a rotating account list.

A missed submission or an inspection finding costs more than time. Our quality management system and regulatory affairs bench run on Nordic ethics: disciplined methodology, unvarnished data and a paper trail that holds up when a regulator asks.

You should not have to choose between full outsourcing and building in-house. We listen to your constraints first, then design the resourcing model with you: you own the team and the plan, we supply the depth, the infrastructure and the flex capacity behind it.